IMMOFINANZ AG

  • WKN: A2JN9W
  • ISIN: AT0000A21KS2
  • Land: Österreich

Nachricht vom 28.08.2019 | 13:18

IMMOFINANZ: Executive Board appointment of CEO Oliver Schumy extended

DGAP-News: IMMOFINANZ AG / Key word(s): Real Estate/Personnel

28.08.2019 / 13:18
The issuer is solely responsible for the content of this announcement.


IMMOFINANZ: Executive Board appointment of CEO Oliver Schumy extended

In today's meeting, the Supervisory Board of IMMOFINANZ AG extended the appointment of CEO Oliver Schumy to the Executive Board by five years from 1 March 2020 to 28 February 2025.

Oliver Schumy has been a member of the IMMOFINANZ Executive Board since 1 March 2015 and has served as the Chief Executive Officer of IMMOFINANZ since 1 May 2015.




On IMMOFINANZ
IMMOFINANZ is a commercial real estate group whose activities are focused on the retail and office segments of seven core markets in Europe: Austria, Germany, Poland, Czech Republic, Slovakia, Hungary and Romania. The core business covers the management and development of properties, whereby the STOP SHOP (retail), VIVO! (retail) and myhive (office) brands represent strong focal points that stand for quality and service. The real estate portfolio has a value of approx. EUR 4.4 billion and covers roughly 220 properties. IMMOFINANZ is listed on the stock exchanges in Vienna (leading ATX index) and Warsaw. Further information under: http://www.immofinanz.com

For additional information contact:
Bettina Schragl
Head of Corporate Communications and Investor Relations
T +43 (0)1 88 090 2290
M +43 (0)699 1685 7290
communications@immofinanz.com
investor@immofinanz.com



28.08.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Expedeon AG mit attraktiver Produktpipeline

Durch die konsequente Fortsetzung der „Grow, Buy & Build“-Strategie hat die im Bereich der Entwicklung und Vermarktung von DNA-Technologien, Proteomik- und Antikörper-Konjugations-Anwendungen tätige Expedeon AG das Umsatzniveau angehoben und auf operativer Ergebnisebene zugleich den Break-Even nachhaltig überschritten. Für die kommenden Perioden ist der Ausbau der Umsatzerlöse mit den bestehenden Produkten geplant. Darüber hinaus verfügt die Expedeon AG über eine attraktive Produktpipeline mit hohem Umsatzpotenzial. Unser Kursziel liegt bei 3,20 € je Aktie. Das Rating lautet KAUFEN.

News im Fokus

Hohes Ergebnis für Q3/2019

18. Oktober 2019, 10:40

Aktuelle Research-Studie

Ahlers AG

Original-Research: Ahlers AG (von GSC Research GmbH): Kaufen

18. Oktober 2019